Advertisement
EQ vs IVA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EQ is a Hold and IVA is a Buy.
EQ sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for EQ moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 43 cases where EQ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EQ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EQ entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EQ's RSI Indicator exited the oversold zone, 26 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on EQ as a result. In 63 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for EQ just turned positive on October 20, 2026. Looking at past instances where EQ's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +2.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EQ advanced for three days, in 224 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.709) is normal, around the industry mean (3.498). P/E Ratio (-16.778) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. EQ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EQ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IVA in upward trend: 10-day moving average crossed above 50-day moving average on November 05, 2026
The 10-day moving average for IVA crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IVA as a result. In 73 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for IVA just turned positive on October 20, 2026. Looking at past instances where IVA's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
IVA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in 175 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 115 of 159 cases where IVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for IVA moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 19 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 53 cases where IVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. IVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.215) is normal, around the industry mean (3.498). P/E Ratio (-7.170) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (136.986) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EQ | IVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 61 | 50 | |
P/E GROWTH RATING 1..100 | 12 | 28 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EQ's Valuation (10) in the Biotechnology industry is significantly better than the same rating for IVA (99) in the null industry. This means that EQ’s stock grew significantly faster than IVA’s over the last 12 months.
EQ's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IVA (100) in the null industry. This means that EQ’s stock grew similarly to IVA’s over the last 12 months.
EQ's SMR Rating (98) in the Biotechnology industry is in the same range as IVA (100) in the null industry. This means that EQ’s stock grew similarly to IVA’s over the last 12 months.
IVA's Price Growth Rating (50) in the null industry is in the same range as EQ (61) in the Biotechnology industry. This means that IVA’s stock grew similarly to EQ’s over the last 12 months.
EQ's P/E Growth Rating (12) in the Biotechnology industry is in the same range as IVA (28) in the null industry. This means that EQ’s stock grew similarly to IVA’s over the last 12 months.
| EQ | IVA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Advances ODDS (%) | 10 days ago 89% | 2 days ago 75% |
| Declines ODDS (%) | 2 days ago 90% | 8 days ago 85% |
| BollingerBands ODDS (%) | N/A | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EQ’s FA Score shows that 2 FA rating(s) are green while IVA’s FA Score has 1 green FA rating(s).
- EQ’s FA Score: 2 green, 3 red.
- IVA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EQ’s TA Score shows that 4 TA indicator(s) are bullish while IVA’s TA Score has 7 bullish TA indicator(s).
- EQ’s TA Score: 4 bullish, 4 bearish.
- IVA’s TA Score: 7 bullish, 3 bearish.
Price Growth
EQ (@Biotechnology) experienced а +1.43% price change this week, while IVA (@Biotechnology) price change was +3.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
EQ is expected to report earnings on Nov 12, 2026.
IVA is expected to report earnings on Nov 23, 2026.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IVA has been loosely correlated with SLDB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if IVA jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To IVA | 1D Price Change % | ||
|---|---|---|---|---|
| IVA | 100% | +1.52% | ||
| SLDB - IVA | 40% Loosely correlated | +6.00% | ||
| MGTX - IVA | 38% Loosely correlated | +0.62% | ||
| IMNM - IVA | 37% Loosely correlated | +2.25% | ||
| CELC - IVA | 37% Loosely correlated | -4.07% | ||
| TVGN - IVA | 37% Loosely correlated | -4.37% | ||
More | ||||